R&D channel feed – Endpoints News

R&D channel feed

Despite mixed data in Alzheimer's agitation, Axsome will still seek FDA approval

4 months ago

CagriSema’s weight loss data disappointed. What does Novo do next?

4 months ago

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

4 months ago

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

4 months ago

GSK's Zejula-Jemperli combo in ovarian cancer hits primary endpoint, misses on overall survival

4 months ago

Aadi starts from scratch as it sells assets, licenses ADCs and raises new funds

4 months ago

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

4 months ago

Regeneron forges ahead in factor XI despite field’s mixed results

4 months ago

Exclusive: Can oral antibodies work? A small startup thinks it has an answer

4 months ago

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

4 months ago

Roche’s Parkinson’s drug flunks second mid-stage trial

4 months ago

Exclusive: Insitro makes headway on the harder road, discovering new ALS drug target

4 months ago

Aurion’s eye cell therapy improves vision in small study, plots Phase 3 trial

4 months ago

Regeneron looks to expand label of Eylea HD early next year

4 months ago

UCB, Novartis say a Phase 2a Parkinson's study failed

4 months ago

Teva and Sanofi step on the gas with anti-TL1A in IBD

4 months ago

Merck winds down TIGIT, LAG-3 programs meant to temper Keytruda erosion

4 months ago

Viridian readies for Tepezza rivalry with new Phase 3 data in thyroid eye disease

4 months ago

Edgewise shares spike on Phase 2 success for muscular dystrophy drug

4 months ago

PureTech declares mid-stage trial win for pulmonary fibrosis drug

4 months ago

Biohaven’s protein degrader cuts antibodies by 60%

4 months ago

Bristol Myers drops cell therapy pacts with Immatics, Century as part of portfolio review

4 months ago

Roche terminates a Phase 3 Spark gene therapy in hemophilia A

4 months ago

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

5 months ago

First page Previous page 11 12 131415 16 17 Next page Last page